EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

CT-based radiomic prognostic vector (RPV) predicts survival and stromal histology in high-grade serous ovarian cancer: an external validation study

Georg J Wengert, Haonan Lu, Eric O Aboagye, Georg Langs, Nina Poetsch, Ernst Schwartz, Zsuzsanna Bagó-Horváth, Christina Fotopoulou, Stephan Polterauer, Thomas H Helbich, Andrea G Rockall

European Radiology · 2024

DOI: 10.1007/s00330-024-11267-5 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Radiology, 2024. Verfasst von Georg J Wengert und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. georg.wengert@meduniwien.ac.at. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tomography, X-Ray Computed, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In women with high-grade serous ovarian cancer (HGSOC), a CT-based radiomic prognostic vector (RPV) predicted stromal phenotype and survival after primary surgery. The study's purpose was to fully externally validate RPV and its biological correlate. Materials and methods In this retrospective study, ovarian masses on CT scans of HGSOC patients, who underwent primary cytoreductive surgery in an ESGO-certified Center between 2002 and 2017, were segmented for external RPV score calculation and then correlated with overall survival (OS) and progression-free survival (PFS). A subset of tissue samples subjected to fibronectin immunohistochemistry were evaluated by a gynaeco-pathologist for stromal content. Kaplan–Meier log-rank test and a Cox proportional hazards model were used for outcome analysis.

Results

Among 340 women with HGSOC, 244 ovarian lesions were available for segmentation in 198 women (mean age 59.8 years, range 34–92). Median OS was 48.69 months (IQR: 27.0–102.5) and PFS was 19.3 months (IQR: 13–32.2). Using multivariate Cox analysis, poor OS was associated with RPV-high (HR 3.17; 95% CI: 1.32–7.60; p = 0.0099), post-operative residual disease (HR 2.04; 95% CI: 1.30–3.20; p = 0.0020), and FIGO stage III/IV (HR 1.79; 95% CI: 1.11–2.86; p = 0.016). Age did not influence OS. RPV-high tissue had higher stromal content based on fibronectin expression (mean 48.9%, SD 10.5%) compared to RPV-low cases (mean 14.9%, SD 10.5%, p < 0.0001). RPV score was not significantly associated with PFS.

Conclusion

Patients with HGSOC and RPV-high ovarian mass on pre-operative CT had significantly worse OS following primary surgery and a higher stromal content compared to RPV-low masses, externally validating the RPV and its biological interpretation. Key Points Question Can the performance of a previously described RPV in women with HGSOC be replicated when licenced to an external institution ?

Findings

External validation of RPV among 244 ovarian lesions demonstrated that, on multivariate analysis, OS was associated with RPV, stage, and postoperative residual disease, replicating previous findings . Clinical relevance External validation of a radiomic tool is an essential step in translation to clinical applicability and provides the basis for prospective validation. In clinical practice, this RPV may allow more personalized decision-making for women with ovarian cancer being considered for extensive cytoreductive surgery .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsTomography, X-Ray ComputedCystadenocarcinoma, SerousHumansFemaleMiddle AgedRetrospective StudiesAgedAdultPrognosisAged, 80 and overNeoplasm GradingCytoreduction Surgical ProceduresRadiomics

Stichwörter der Autor:innen

Computed tomographyExternal validationFibronectinHigh-grade serous ovarian cancerRadiomic prognostic vector

Autor:innen und Institutionen

  • Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. georg.wengert@meduniwien.ac.at.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. georg.wengert@meduniwien.ac.at.
  • Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
  • Computational Imaging Research Laboratory, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
  • Department of Pathology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.

Zitieren

APA

Wengert, G. J., Lu, H., Aboagye, E. O., Langs, G., Poetsch, N., Schwartz, E., Bagó-Horváth, Z., Fotopoulou, C., Polterauer, S., Helbich, T. H., & Rockall, A. G. (2024). CT-based radiomic prognostic vector (RPV) predicts survival and stromal histology in high-grade serous ovarian cancer: an external validation study. European Radiology. https://doi.org/10.1007/s00330-024-11267-5

Vancouver

Wengert GJ, Lu H, Aboagye EO, Langs G, Poetsch N, Schwartz E, et al. CT-based radiomic prognostic vector (RPV) predicts survival and stromal histology in high-grade serous ovarian cancer: an external validation study. European Radiology. 2024. doi:10.1007/s00330-024-11267-5

BibTeX
@article{Wengert2024,
  author = {Wengert, Georg J and Lu, Haonan and Aboagye, Eric O and Langs, Georg and Poetsch, Nina and Schwartz, Ernst and Bagó-Horváth, Zsuzsanna and Fotopoulou, Christina and Polterauer, Stephan and Helbich, Thomas H and Rockall, Andrea G},
  title = {CT-based radiomic prognostic vector (RPV) predicts survival and stromal histology in high-grade serous ovarian cancer: an external validation study},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-11267-5}
}
Kostenlos starten →